Home›Trial›NCT06112327

NCT06112327Enrolling by invitation

Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease

Study Summary

LTF-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by the sponsor to evaluate the long-term effects of the investigational therapy. Participants will be followed for a total of 15 years after the first administration of the gene-editing therapy.

Conditions

Atherosclerotic Cardiovascular Disease Heterozygous Familial Hypercholesterolemia Hypercholesterolemia

Interventions / Drugs

View on ClinicalTrials.gov ↗

Sponsor

Verve Therapeutics

Study Details

Enrollment116 participants

Primary Completion2039-10

Lead SponsorVerve Therapeutics, Inc.

Data Retrieved2026-10-14

What This Trial Means for Biotech Investors

Trial Phase Context

Status & Expected Data

Current status: Enrolling by invitation.

Primary completion: 2039-10

Enrolled: 116 participants

Sponsor Catalyst Profile

Verve Therapeutics (VERV) is the sponsoring company for this trial. BiotechSign currently grades this company F (6/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

VERV Full Pipeline →All Companies →

Other Trials from Verve Therapeutics

NCT06164730A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature…(PHASE1)NCT06451770Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia(PHASE1)

Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.